224 related articles for article (PubMed ID: 35004241)
1. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
Kundu K; Cardnell RJ; Zhang B; Shen L; Stewart CA; Ramkumar K; Cargill KR; Wang J; Gay CM; Byers LA
Transl Lung Cancer Res; 2021 Nov; 10(11):4095-4105. PubMed ID: 35004241
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW; Zhang Y; Elmeskini R; Zimmermann A; Fu H; Murai Y; Wangsa D; Kumar S; Takahashi N; Atkinson D; Saha LK; Lee CF; Elenbaas B; Desai P; Sebastian R; Sharma AK; Abel M; Schroeder B; Krishnamurthy M; Kumar R; Roper N; Aladjem M; Zenke FT; Ohler ZW; Pommier Y; Thomas A
EMBO Mol Med; 2023 Aug; 15(8):e17313. PubMed ID: 37491889
[TBL] [Abstract][Full Text] [Related]
3. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
4. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
[TBL] [Abstract][Full Text] [Related]
6. The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs.
Jo U; Arakawa Y; Zimmermann A; Taniyama D; Mizunuma M; Jenkins LM; Maity T; Kumar S; Zenke FT; Takebe N; Pommier Y
Mol Cancer Ther; 2024 Mar; ():. PubMed ID: 38466804
[TBL] [Abstract][Full Text] [Related]
7. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
[TBL] [Abstract][Full Text] [Related]
8. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
Cancer Treat Rev; 2024 May; 128():102768. PubMed ID: 38797062
[TBL] [Abstract][Full Text] [Related]
10. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
Mao S; Chaerkady R; Yu W; D'Angelo G; Garcia A; Chen H; Barrett AM; Phipps S; Fleming R; Hess S; Koopmann JO; Dimasi N; Wilson S; Pugh K; Cook K; Masterson LA; Gao C; Wu H; Herbst R; Howard PW; Tice DA; Cobbold M; Harper J
Mol Cancer Ther; 2021 Mar; 20(3):541-552. PubMed ID: 33653945
[TBL] [Abstract][Full Text] [Related]
11. De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.
Chakraborty S; Coleman C; Manoj P; Demircioglu D; Shah N; de Stanchina E; Rudin CM; Hasson D; Sen T
Clin Cancer Res; 2023 Sep; 29(17):3526-3540. PubMed ID: 37382635
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
[TBL] [Abstract][Full Text] [Related]
13. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.
Krushkal J; Silvers T; Reinhold WC; Sonkin D; Vural S; Connelly J; Varma S; Meltzer PS; Kunkel M; Rapisarda A; Evans D; Pommier Y; Teicher BA
Clin Epigenetics; 2020 Jun; 12(1):93. PubMed ID: 32586373
[TBL] [Abstract][Full Text] [Related]
14. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Zhang B; Stewart CA; Wang Q; Cardnell RJ; Rocha P; Fujimoto J; Solis Soto LM; Wang R; Novegil V; Ansell P; He L; Fernandez L; Jendrisak A; Gilbertson C; Schonhoft JD; Byun J; Jones J; Anderson AKL; Aparicio A; Tran H; Negrao MV; Zhang J; Wang WL; Wistuba II; Wang J; Wenstrup R; Byers LA; Gay CM
Br J Cancer; 2022 Aug; 127(3):569-576. PubMed ID: 35440668
[TBL] [Abstract][Full Text] [Related]
15. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
[TBL] [Abstract][Full Text] [Related]
16. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
17. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Murai J; Thomas A; Miettinen M; Pommier Y
Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
[TBL] [Abstract][Full Text] [Related]
19. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer-A Prospective Pilot Study.
Simić I; Guzonjić A; Kotur Stevuljević J; Ćeriman Krstić V; Samardžić N; Savić Vujović K; Jovanović D
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
